## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -10.8% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($357.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Liontrust Investment Partners LLP Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251215T110934 | Bullish | Relevance: 100%
- Liontrust Investment Partners LLP reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 32.4% in the second quarter, selling over 6,000 shares. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus rating for ALNY with an average price target of $482.71. The article also notes recent insider selling activity, with corporate insiders divesting substantial shares in the last quarter.

**2. A look at Alnylam Pharmaceuticals (ALNY) valuation after Nasdaq 100 inclusion and convertible notes repurchase**
- Source: Simply Wall Street | 20251214T091009 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) recently joined the Nasdaq 100 and repurchased some 2027 convertible notes, impacting its visibility and capital structure. Despite recent share price cooling, the company shows strong long-term momentum with significant year-to-date and 5-year returns. While currently trading at a discount to consensus targets and considered 19.3% undervalued based on TTR revenue scaling, its price-to-sales ratio is higher than industry averages, suggesting potential valuation risk.

**3. Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index**
- Source: GuruFocus | 20251213T140832 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) and Seagate Technology Holdings (STX) are set to join the Nasdaq 100 Index as part of its annual reconstitution, effective December 22, 2025. This inclusion is significant as major index funds like the Invesco QQQ Trust Series 1 ETF will adjust holdings, impacting the companies involved. Alnylam, a leader in RNA interference therapeutics, has a market capitalization of $52.52 billion and shows robust revenue growth but also a high debt-to-equity ratio and notable insider selling.

**4. Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $351.00 by Analysts at Leerink Partners**
- Source: MarketBeat | 20251215T210733 | Somewhat-Bearish | Relevance: 100%
- Leerink Partners has reduced its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $370.00 to $351.00, maintaining a "market perform" rating despite the biopharmaceutical company's average "Moderate Buy" rating among analysts. Other firms have issued varying price target adjustments and ratings, while insider transactions reveal recent stock sales by company executives. Institutional investors have also significantly adjusted their holdings in ALNY.

**5. China Universal Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251214T101010 | Neutral | Relevance: 100%
- China Universal Asset Management Co. Ltd. significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 10.2% in the second quarter, selling over 3,000 shares. Despite this reduction, Alnylam remains a substantial holding for the firm, representing about 0.9% of its assets. The article also highlights recent insider selling from top executives and broadly positive analyst sentiment with a "Moderate Buy" rating and an average price target of $482.71.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Leerink Partner | $351 | $370 | -5% |
| 2025-12-11 | Stifel | $508 | $495 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Leerink Partner | main | Market Perform |
| 2025-12-11 | Stifel | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.03M) |
| Sells | 9 ($1.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Near-term weakness: 13.2% below SMA50 despite long-term uptrend.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 36.9x attractive for 114% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 43% YoY. Insider selling cluster ($1.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $51.7B |
| Beta | 0.30 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 36.9 |
| Current P/E | 78.9 |
| YoY Growth | 113.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -9.7% to -10.8% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 14.8pp (needs >4.0% for momentum thesis). AM_20 at -11.0% indicates price below own 20MA trend. Underperforming sector by 12.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram bearish (-6.38), momentum weakening. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -10.78% (CS: 2) | Weak |
| RSI_14 | 31.3 | Neutral |
| MACD Histogram | -6.38 | Bearish |
| vs SMA20 | 0.890x | Below |
| vs SMA50 | 0.868x | Below |
| vs SMA200 | 1.080x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $391.50
- **Stop Loss:** $357.00 (8.8% risk)
- **Target:** $426.00 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 34
- **Position Value:** $13,311.00
- **Portfolio %:** 13.31%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*